Week In Review: CStone Out-Licenses Ex-China Rights To Two Immunotherapies In $1.3 Billion Deal
October 31, 2020 at 14:05 PM EDT
CStone Pharma out-licensed global rights for two immunoncology assets to US-based EQRx in a $1.3 billion agreement. CStone will receive $150 million upfront and up to $1.15 billion in milestone payments, plus royalties.
